Trifecta-Heart cfDNA-MMDx Study
ConditionHeart Transplant Rejection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Alberta
About this trial
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.
Eligibility criteria
Qualifiers
All heart transplant recipients undergoing a biopsy for clinical indications and protocol biopsies, as determined by their physician or surgeon, will be eligible to enroll in the study.
Patients are enrolled based on standard of care biopsies, including surveillance biopsies in high-risk patients, with informed consent.
Disqualifiers
Patients will be excluded from the study if they decline participation
Are unable to give informed consent.
Recipients of multiple organs.
Trial design
Treatments tested in this trial
- MMDx diagnostic test
- Prospera
- HLA antibody
Treatment groups
300 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov